Innovation and biomarkers in cancer drug development (IBCD) 2018

  • Email
  • Help


TitleInnovation and biomarkers in cancer drug development (IBCD) 2018
Date29/11/2018 - 30/11/2018
LocationBrussels, Belgium
SummaryThe innovation and biomarkers in cancer drug development (IBCD) 2018 event will embrace the full environment and explore routes through the constantly evolving scientific, methodological and regulatory environment. The combined efforts of the European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI), European Medicines Agency (EMA), and American Association for Cancer Research (AACR) with the involvement of Food and Drug Administration (FDA) and Pharmaceuticals and Medical Devices Agency (PMDA) and health technology assessment specialists will result in a unique program. The 2018 edition will build upon the recommendations and action points decided upon at the IBCD 2016 edition. Topics, which will be developed, will include items like health technology assessment (HTA) of biomarker assays, comparative effectiveness research and the translation of findings of clinical trials into daily practice.

All documents

Media Videos


  • Registration open until 15/11/2018

External links

Contact point:

Jennifer Crespo

Follow the event on Twitter #IBCD2018